Diabetes medications

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

A randomized trial supports giving people with obesity liraglutide to maintain weight loss after an 8-week diet, particularly if it is combined with regular vigorous exercise.

Click through to read more on this announcement

Older people with type 2 diabetes are more likely to receive inappropriately intensive glucose-lowering treatment if they live in high- versus middle income countries, show data from the global DISCOVER study.

Suboptimal medication-taking identified through urine testing is associated with a higher prevalence of microvascular and macrovascular complications in people with type 2 diabetes than found with consistent usage, report researchers.

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

Results from a US retrospective study suggest that usage rates of SGLT2 inhibitors remain low in people with type 2 diabetes, particularly among Black and Asian individuals, women, and lower-income groups.

Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.

Combining metformin with a sulfonylurea produces poorer non-glycemic outcomes than combining it with other second-line agents, show results from the global DISCOVER program.

Researchers have found that people taking metformin for type 2 diabetes are less likely to be hospitalized or die due to pneumonia than those taking other glucose-lowering medications.

Adding dapagliflozin to standard care improves outcomes for people with heart failure and reduced ejection fraction irrespective of sex, suggests a prespecified subgroup analysis of the DAPA-HF trial.

Findings from a US randomized controlled trial suggest that add-on treatment with the SGLT2 inhibitor dapagliflozin reduces levels of some vasoconstrictors and increases some vasodilators in people with type 2 diabetes.

Black West African men have lower levels of insulin secretion in response to a meal than their White Northern European counterparts, irrespective of insulin sensitivity, study findings indicate.

A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.